Uterine Bleeding ≠ Endometrial Cancer: Don't Let Abnormal Signals Turn into Excessive Panic
In the gynecology clinic waiting area, you can often overhear conversations like: "Doctor, my period hasn't stopped for half a month — could it be cancer?" "I've been postmenopausal for three years and suddenly started bleeding again — is something seriously wrong with my uterus?" Abnormal uterine bleeding is one of the most common presenting complaints among women, and the most panic-inducing aspect is equating "bleeding" directly with "endometrial cancer." In reality, uterine bleeding is a "warning signal" from the body, but behind this signal may lie multiple causes — endometrial cancer is only one of them, not the whole story.
I. What Is Abnormal Uterine Bleeding?
Simply put, it's "irregular menstruation": periods that don't come when expected, bleeding when it shouldn't occur, periods lasting more than 7 days, or bleeding so heavy that you soak through a sanitary pad every hour (even leading to anemia).
II. The "Hidden Culprits" Behind Bleeding: 90% Are Benign
Endometrial cancer may present with bleeding as a first symptom (especially in postmenopausal women), but over 90% of abnormal bleeding is benign. Common causes include:
- Hormonal imbalance: Pubertal/perimenopausal ovarian dysfunction (most common);
- Structural uterine issues: Uterine fibroids (submucosal type), endometrial polyps, adenomyosis;
- Others: Pelvic inflammatory disease, coagulation disorders, etc.
- High-risk alert: Only about 1%–10% of bleeding is related to endometrial cancer, and it is most common in women over 50 who are obese, diabetic, chronically anovulatory (e.g., PCOS), or have a family history.
III. What Bleeding Signals Should Raise Concern?
If you experience any of the following, seek medical evaluation promptly:
- Postmenopausal bleeding (even just a spot on underwear);
- Bleeding lasting >7 days, or repeated "periods" within one month;
- Heavy bleeding (e.g., soaking a pad every hour) accompanied by dizziness or fatigue;
- Foul-smelling discharge, sudden weight loss, or decreased appetite.
IV. What to Expect at the Doctor: Pathology Is the "Gold Standard"
Physicians will determine the cause through the following steps:
- Initial evaluation: Gynecologic ultrasound (assessing endometrial thickness, uterine/ovarian structure), complete blood count;
- Key diagnostic procedure: Hysteroscopy + D&C (directly visualizing the endometrium and obtaining tissue for pathology — the pathology result determines the nature);
- Supplementary tests: Sex hormones (assessing ovarian function), tumor markers (auxiliary assessment).
V. New Genetic Testing Technology Leading Non-invasive Endometrial Cancer Screening:
In recent years, the National Medical Products Administration (NMPA) approved the first Class III medical device for endometrial cancer methylation testing — a global first. Among these, CISENDO® (Human CDO1/CELF4 Gene Methylation Detection Kit) offers the following technical advantages through non-invasive sampling and high-sensitivity detection:
-
Non-invasive sampling: Cervical secretion collection replaces traditional D&C, improving patient compliance by 60%
-
Dual-gene combined detection: CDO1 + CELF4 methylation combined testing achieves a sensitivity of 95%
-
Rapid diagnosis: Completed in the outpatient setting with results in 3 hours — an 80% reduction in turnaround time
-
Cost advantage: Testing costs only 30%–50% of hysteroscopic pathology
VI. Even If It's Not Cancer, Don't Delay!
Long-term abnormal bleeding may lead to anemia, infection, or mask other conditions (such as growing fibroids or polyp malignant transformation). Benign lesions can be managed with medication (hormone regulation) or surgery (hysteroscopic polyp/fibroid removal). The 5-year survival rate for early-stage (Stage I) endometrial cancer exceeds 90% — early detection is key.
Summary:
Uterine bleeding is a "health questionnaire" your body sends — the answer might be a minor hormonal issue, a fibroid alert, or a cancer warning. Methylation testing means you don't need to panic blindly, but don't delay either. Pay attention to menstrual changes (cycle, volume, regularity), have regular postmenopausal ultrasounds, and seek prompt medical attention when bleeding is abnormal. When any test — especially methylation — yields a positive result, hysteroscopy is indispensable. With a negative methylation result, you can work with your physician with peace of mind to manage benign uterine conditions and jointly safeguard your health.
The purpose of medicine is to help us read our body's signals and protect health through science!
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.